These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34528216)

  • 1. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Cicala G; Santoro V; Cutroneo PM; Franchina T; Spina E
    Drugs Real World Outcomes; 2022 Mar; 9(1):91-107. PubMed ID: 34528216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database.
    Barbieri MA; Sorbara EE; Cicala G; Santoro V; Cutroneo PM; Franchina T; Santarpia M; Silvestris N; Spina E
    Front Oncol; 2022; 12():1005626. PubMed ID: 36505840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
    Waliany S; Caswell-Jin J; Riaz F; Myall N; Zhu H; Witteles RM; Neal JW
    JACC CardioOncol; 2023 Feb; 5(1):85-98. PubMed ID: 36875913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.
    Barbieri MA; Sorbara EE; Battaglia A; Cicala G; Rizzo V; Spina E; Cutroneo PM
    Front Pharmacol; 2022; 13():808370. PubMed ID: 35281926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database.
    Magro L; Arzenton E; Leone R; Stano MG; Vezzaro M; Rudolph A; Castagna I; Moretti U
    Front Pharmacol; 2020; 11():622862. PubMed ID: 33536925
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
    Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
    J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous reporting of adverse reactions related to proton pump inhibitors.
    Dipasquale V; Cicala G; Laganà F; Cutroneo P; Trimarchi G; Spina E; Romano C
    Dig Liver Dis; 2023 May; 55(5):595-600. PubMed ID: 36404233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).
    Bao Y; Chen J; Duan L; Wang F; Lai H; Mo Z; Zhu W
    Front Pharmacol; 2024; 15():1288362. PubMed ID: 38327983
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
    Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.
    Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.